Evidence map›Paper›PMID 23804582›Full record

Trial reportObesity (Silver Spring, Md.)2014

Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program.

Catherine Kim, Elizabeth Barrett-Connor, John F Randolph, Shengchun Kong, Bin Nan, Kieren J Mather, Sherita H Golden, Diabetes Prevention Program Research Group

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Catherine KimDepartments of Medicine and Obstetrics & Gynecology, University of Michigan, Ann Arbor, Michigan, USA.
Elizabeth Barrett-Connor
John F Randolph
Shengchun Kong
Bin Nan
Kieren J Mather
Sherita H Golden
Diabetes Prevention Program Research Group
University of Michigan–Ann Arbor · USIndiana University Bloomington · USJohns Hopkins University · USUniversity of California, San Diego · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Tomas Vaisar · 1986 to 2026
$41.4M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI AHIMA, REXFORD S. · 2013 to 2017
$9.7M
Post DPP Followup StudyU01DK048406 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI DE GROOT, MARY K. · 1994 to 2021
$9.1M
Sex Hormones in Postmenopausal Women in the Diabetes Prevention ProgramR01DK083297 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KIM, CATHERINE · 2010 to 2012
$1.1M
Type 2 Diabetes Risk in Women With Gestational DiabetesK23DK071552 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KIM, CATHERINE · 2006 to 2010
$674k
Intramural NIH HHSNCATS NIH HHS UL1 TR000041NCATS NIH HHS UL1 TR001449NIDDK NIH HHS K23 DK071552NIDDK NIH HHS K23DK071552NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK079637NIDDK NIH HHS R01 DK083297NIDDK NIH HHS R01DK083297NIDDK NIH HHS U01 DK048406NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01DK048489
6 · The paper itself

Abstract

objectivesTo examine whether estrogen use potentiates weight loss interventions via sex steroid levels and whether endogenous sex steroid levels predict response to weight loss interventions among women not using estrogen.

methodsThe Diabetes Prevention Program randomized overweight or obese dysglycemic participants to lifestyle change with the goals of weight reduction of >7% of initial weight and 150 minutes per week of exercise, metformin, or placebo. In this secondary analysis, we examined sex steroid levels and reductions in weight and waist circumference (WC) among postmenopausal women using (n = 324) and not using (n = 382) oral estrogen.

resultsEstrogen users and nonusers randomized to lifestyle change and metformin both lost significant amounts of weight compared to placebo. Reductions in weight and WC over 1 year associated with randomization arm were not associated with baseline sex steroid levels among estrogen users or nonusers.

conclusionsAmong estrogen users, baseline sex steroids were not associated with reductions in weight or WC, suggesting that exogenous estrogen does not potentiate weight loss by altering sex steroids. Among nonestrogen users, baseline sex steroids were not associated with reductions in weight or WC.

Indexed as

AdultAgedBlood GlucoseBody Mass IndexFemaleFollow-Up StudiesGonadal Steroid HormonesHumansHypoglycemic AgentsLife StyleLinear ModelsMetforminMiddle AgedMotor ActivityObesityOverweightBlood GlucoseGonadal Steroid HormonesHypoglycemic AgentsMetformin

Identifiers

PMID23804582
PMCPMC3818475
OpenAlexW2111648493

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.